Islamova Kamola Akramovna (1)
Acute respiratory infections significantly contribute to the development and progression of cardiovascular diseases and their complications. The innate immune system, particularly interferons (IFN), serves as the first line of defense against viral pathogens. A deficiency of type I IFN, commonly observed in elderly patients with cardiovascular comorbidities, predisposes to a more severe course of viral infections. Growing vaccine hesitancy has further limited preventive strategies. In this context, antiviral drugs present a valuable alternative, offering advantages such as applicability in broad population groups, including immunocompromised individuals, and expanding therapeutic and preventive options for respiratory viral infections, including COVID-19. However, certain antiviral agents may induce oxidative stress, thereby aggravating its already elevated level during viral infections. To mitigate this effect, combining antiviral therapy with antioxidants appears rational. Recombinant IFN alpha-2b in combination with ascorbic acid and tocopherol provides such a therapeutic opportunity, enhancing both antiviral efficacy and oxidative stress control in patients with cardiovascular diseases at risk of severe respiratory viral infections.
1. Ibrat A. et al. FEATURES OF THE SYNDROMES OF OSTEOPOROSIS AND SARCOPENIA IN RHEUMATOID ARTHRITIS WITH MUSCLE WEAKNESS //Spectrum Journal of Innovation, Reforms and Development. – 2023. – Т. 13. – С. 95-103.
2. Akramovna I. K., Sanatovich T. E. Functional evaluation of the effectiveness of intrаarticular chondro hyaluronic injection in early knee osteoarthritis //Journal of Critical Reviews. – 2020. – Т. 7. – №. 7. – С. 410-413.
3. Islamova K. A., Sh K. F., Toirov E. S. Efficiency Of Intra-Articular Administration In Early Osteoarthrosis //The American Journal of Medical Sciences and Pharmaceutical Research. – 2020. – Т. 2. – №. 11. – С. 22-27.
4. Shamsiev E. А., Islamova K. A., Ziyadullayev Sh X. ARTERIAL HYPERTENSION IN PATIENTS WITH COVID-19 //Scholastic: Journal of Natural and Medical Education. – 2023. – Т. 2. – №. 11. – С. 13-18.
5. Абдушукурова К. Р. и др. Суставной Синдром При Хронических Воспалительных И Дистрофических Заболеваниях Суставов //Miasto Przyszłości. – 2023. – Т. 33. – С. 209-214.
6. Абдушукурова К., Исламова К. ВЗАИМОСВЯЗЬ НЕРВНО-ЭНДОКРИННЫХ НАРУШЕНИЙ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ //International Bulletin of Medical Sciences and Clinical Research. – 2023. – Т. 3. – №. 11. – С. 16-20.
7. Amrillaevich A. I. et al. EFFECTIVENESS OF LASER PHYSIOTHERAPY METHOD IN TREATMENT OF PRIMARY KNEE JOINT OSTEOARTHRITIS //International Conference on Medicine and Life Sciences. – 2023. – С. 76-82.
8. Исламова К. А. и др. ЭФФЕКТИВНОСТЬ ВНУТРИСУСТАВНОГО ВВЕДЕНИЯ ГИАЛУРОМ ХОНДРО ПРИ РАННЕМ ОСТЕОАРТРОЗЕ //IQRO. – 2023. – Т. 2. – №. 2. – С. 186-193.
9. Тоиров Э., Исломова К., Уралов Р. Эффективность комплексного лечения раннего остеоартроза //Журнал вестник врача. – 2019. – Т. 1. – №. 3. – С. 99-103.
10. Исломова К. А., Тоиров Э. С. Эффективность внутрисуставного введения хондропротекторов при раннем остеоартрозе //Вестник науки и образования. – 2020. – №. 9-3 (87). – С. 92-97.
11. Hamrayev B. E. et al. SYSTEMIC LUPUS ERYTHEMATOSUS AND RENAL LESIONS: CLINICOPATHOGENETIC ASPECTS //American Journal of Pediatric Medicine and Health Sciences (2993-2149). – 2023. – Т. 1. – №. 9. – С. 482-489.
12. Akramovna I. K., Rafikovna U. K., Ergashevna E. N. Current Perceptions of Chronic Pancreatitis //International Journal of Alternative and Contemporary Therapy. – 2024. – Т. 2. – №. 1. – С. 12-16.
13. Akramovna I. K., Alisherovna K. M. CAUSES OF ARRHYTHMIA DURING PREGNANCY //Journal of new century innovations. – 2024. – Т. 45. – №. 3. – С. 34-41.
14. Akramovna I. K., Zaynobiddin o’g’li F. J. RISK FACTORS OF EARLY DEVELOPED OSTEOARTHRITIS //BEST SCIENTIFIC RESEARCH-2023. – 2023. – Т. 2. – №. 1. – С. 28-35.
15. Zoxidjonovna R. M., Amrullayevich А. I. METHODS OF REHABILITATION OF TRAUMATIC INJURIES OF THE ANKLE JOINT IN FOOTBALL PLAYERS //JOURNAL OF BIOMEDICINE AND PRACTICE. – 2023. – Т. 8. – №. 3.
16. Хамраева Н. А. COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS DEPENDING ON CLIMATE AND GEOGRAPHICAL CHARACTERISTICS //УЗБЕКСКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ. – 2022. – Т. 3. – №. 5.
17. Alisherovna K. M. et al. QUALITY OF LIFE IN THE PATHOLOGY OF THE CARDIOVASCULAR SYSTEM //World Bulletin of Public Health. – 2023. – Т. 25. – С. 35-40.
18. IBRAGIMOV K. et al. The Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis Treated with Conventional DMARDs: a Clinic Based Case Control Study. – 2022.
19. Исламова К. А., Тоиров Э. С. EATURES OF CLINICAL CHARACTERISTICS OF OSTEOARTHROSIS ON THE BACKGROUND OF OBESITY //Новый день в медицине. – 2019. – №. 2. – С. 167-170.
20. Hamraeva N. A., Sultonov I. I., Hasanov F. S. Systemic lupus erythematosus treatment strategy //Journal of Critical Reviews. – 2020. – Т. 7. – №. 9. – С. 269-270.
21. Martin S.S., Aday A.W., Almarzooq Z.I. et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149(8):e347–e913. DOI: 10.1161/CIR.0000000000001209
22. Henein M.Y., Vancheri S., Longo G., Vancheri F. The Role of Inflammation in Cardiovascular Disease. Int J Mol Sci. 2022;23(21):12906. DOI: 10.3390/ijms232112906
23. Ohland J., Warren-Gash C., Blackburn R. et al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark, 2010 to 2016. Euro Surveill. 2020;25(17):1900199. DOI: 10.2807/1560-7917.ES.2020.25.17.1900199
24. van Royen F.S., Venekamp R.P., Bruijning-Verhagen P.C.J.L., Rutten F.H. Acute Respiratory Infections Fuel Cardiovascular Disease. J Am Coll Cardiol. 2024;84(25):2468–2470. DOI: 10.1016/j.jacc.2024.10.079
25. Clarke M., Falcione S., Boghozian R. et al. Viral Infection and Ischemic Stroke: Emerging Trends and Mechanistic Insights. J Am Heart Assoc. 2024;13(18):e035892. DOI: 10.1161/JAHA.124.035892
26. Sethi N.J., Safi S., Korang S.K. et al. Antibiotics for secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2021;2(2):CD003610. DOI: 10.1002/14651858.CD003610.pub4
27. Liprandi Á.S., Liprandi M.I.S., Zaidel E.J. et al. Influenza vaccination for the prevention of cardiovascular disease in the Americas: consensus document of the Inter-American Society of Cardiology and the World Heart Federation. Glob Heart. 2021;16(1):55. DOI: 10.5334/gh.1069
28. Fröbert O., Götberg M., Erlinge D. et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebocontrolled, multicenter trial. Circulation. 2021;144(18):1476–1484. doi.org/10.1161/circulationaha.121.057042
29. Byrne R.A., Rossello X., Coughlan J.J. et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. DOI: 10.1093/eurheartj/ehad191
30. Shao H.H., Yin R.X. Pathogenic mechanisms of cardiovascular damage in COVID-19. Mol Med. 2024;30(1):92. DOI: 10.1186/s10020-024-00855-2
31. Jin S., Kang P.M. A Systematic Review on Advances in Management of Oxidative Stress-Associated Cardiovascular Diseases. Antioxidants (Basel). 2024;13(8):923. DOI: 10.3390/antiox13080923
32. Costa B., Gouveia M.J., Vale N. Oxidative Stress Induced by Antivirals: Implications for Adverse Outcomes During Pregnancy and in Newborns. Antioxidants (Basel). 2024;13(12):1518. DOI: 10.3390/antiox13121518
33. Xie J., Yuan C., Yang S. et al. The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death. Cell Mol Biol Lett. 2024;29(1):138. DOI: 10.1186/s11658-024-00659-6
34. Zhang Q., Meng Y., Wang K. et al. Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19. Front Immunol. 2021;12:631226. DOI: 10.3389/fimmu.2021.631226
35. El-Sayed W.M., Al-Kahtani M.A. Potential adverse effects of oseltamivir in rats: males are more vulnerable than females. Can J Physiol Pharmacol. 2011;89(9):623–630. DOI: 10.1139/y11-060
36. Aleem A., Mahadevaiah G., Shariff N., Kothadia J.P. Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. Proc (Bayl Univ Med Cent). 2021;34(4):473–477. DOI: 10.1080/08998280.2021.1885289
37. Sebastiani G., Navarro-Tapia E., Almeida-Toledano L. et al. Effects of Antioxidant Intake on Fetal Development and Maternal/Neonatal Health during Pregnancy. Antioxidants (Basel). 2022;11(4):648. DOI: 10.3390/antiox11040648
38. O’Mahoney L.L., Routen A., Gillies C. et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762. DOI: 10.1016/j.eclinm.2022.101762.